Developing a comprehensive fetal anomalies gene panel for the NHS England Genomic Medicine Service

Anna de Burca\textsuperscript{1}, Rhiannon Mellis\textsuperscript{2,4}, Rebecca E. Foulger\textsuperscript{1,3}, Ellen M. McDonagh\textsuperscript{1} Richard H. Scott\textsuperscript{1,2}, Lyn S. Chitty\textsuperscript{2,4}

\textsuperscript{1}Genomics England, Queen Mary University of London, Charterhouse Square, London, UK
\textsuperscript{2}London North Genomic Laboratory Hub, Great Ormond Street NHS Foundation Trust, London, UK
\textsuperscript{3}Genomics England, Biodata Innovation Centre, Wellcome Genome Campus, Cambridge, UK
\textsuperscript{4}Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK

Panel publicly available from PanelApp: https://panelapp.genomicsengland.co.uk/panels/478 and the PanelApp API

Background

Virtual gene panels are widely used by clinical diagnostic services to prioritise potentially disease-causing variants identified by next-generation sequencing. Genomics England’s PanelApp (https://panelapp.genomicsengland.co.uk) is a publicly available tool originally developed to support the 100,000 Genomes Project analysis pipeline. Subsequent to the 100,000 Genomes Project, the NHS is implementing a Genomic Medicine Service in England that will include rapid exome sequencing for fetuses with multiple abnormalities where a monogenic malformation disorder is considered the likely aetiology. Fetal exome results will be returned within the time frame of a pregnancy and may inform decision-making, thus genes included in this panel must be based on robust gene-disease associations and relevant to the fetus, i.e. associated with structural anomalies known to be, or that could potentially be, detected in fetal life.

Objective

To develop and validate a virtual gene panel of fetally relevant genes to prioritise potentially disease-causing variants identified by whole exome sequencing as part of the NHS England Genomic Medicine Service rapid fetal exome service.

Methods

The PanelApp curation platform was used to develop the virtual panel. Genes rated as ‘Confirmed’ in the Developmental Disorders Gene2Phenotype database (DDG2P) and additional genes reported in four recent, large scale studies of fetal exome/genome sequencing were systematically reviewed to determine the suitability of each gene for inclusion.

Results and Validation

A total of 964 genes meeting inclusion criteria were identified and included as diagnostic grade in the fetal panel. The panel gene content was validated using a cohort of 197 patients with genetic diagnoses made through the 100,000 Genomes Project, where the clinical phenotype included one or more fetally relevant features.

Validation of the panel using data from the 100,000 Genomes Project demonstrated that the review process was effective at defining fetally relevant genes. The main reason for the non-inclusion of genes from the panel was that the gene did not have a ‘Confirmed’ rating in DDG2P, and was therefore not reviewed for inclusion in the panel. A pathogenic variant was found in MFS08, which had been reviewed as not fetally relevant due to the reported age of onset. This gene will be included in future iterations of the panel. This finding also prompted review of other genes associated with neuronal ceroid lipofuscinosis, as it highlighted the possibility of unrerecognised fetal phenotypes in this condition.

Conclusions

We have developed a publicly available comprehensive fetal anomalies gene panel covering a wide range of clinically relevant fetal structural anomalies. Validation of the panel demonstrated that the panel sensitivity is high, but would be improved by

- systematically reviewing all genes currently rated as Probable or Possible in DDG2P for new evidence of disease association
- drawing on additional sources of fetally relevant genes

Lack of awareness of fetal phenotypes for known postnatal conditions, and identification of new conditions presenting prenatally mean that this panel will require regular updates.

Future use in the NHS Genomic Medicine Service will permit further validation and refinement of the panel.

Acknowledgements

RM is fully and LSC partially funded by the Great Ormond Street NHS Biomedical Research Centre. Other authors are all funded by Genomics England Limited, a wholly owned company of the Department of Health funded by the NIHR and NHS England, the Wellcome Trust, Cancer Research UK and the Medical Research Council. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.